Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

136.19 USD +3.27 (+2.46%)
Streaming Delayed Price Updated: 12:19 PM EDT, May 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 184,758
Open 133.68
Bid (Size) 136.06 (3)
Ask (Size) 136.33 (1)
Prev. Close 132.92
Today's Range 131.58 - 136.44
52wk Range 119.29 - 178.41
Shares Outstanding 117,545,040
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam Announces New Advances in ATTR Amyloidosis Program
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has started a clinical study of a biannual dosing regimen of vutrisiran, an investigational... 
From Business Wire News Releases
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences which are being held... 
From Business Wire News Releases

Performance

YTD
+6.32%
+6.32%
1 Month
-0.03%
-0.03%
3 Month
-17.65%
-17.65%
6 Month
+2.83%
+2.83%
1 Year
-2.34%
-2.34%

More News

Read More
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
From Business Wire News Releases
Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
From Business Wire News Releases
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
From Business Wire News Releases
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
From Business Wire News Releases
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
From Business Wire News Releases
Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
From Business Wire News Releases
Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine
From Business Wire News Releases
Analysts Anticipate QQQJ Will Reach $37
Tags ETFs
From ETF Channel
Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript
Tags ALNY Market News
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.